Skip to Main Content

Decibel Therapeutics CEO Steven Holtzman is really, officially retiring.

The departure of the longtime vet of Boston’s biotech scene — he was formerly an executive vice president at Biogen and CEO of the cancer-focused Infinity Pharmaceuticals — is part of a broader restructuring at Decibel. The company is also ditching some early discovery programs and narrowing its scientific focus to regenerating damaged cells and structures in the ear that cause hearing and balance disorders.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.